CCO Independent Conference Coverage
|
2009 American Society of Clinical Oncology Annual Meeting*
May 29-June 2, 2009 | Orlando, Florida
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Choose from 4 tracks of coverage (mouse over track for more info)
|
Expert Recaps and Slidesets
|
Breast Cancer Expert Recap
William J. Gradishar, MD, FACP, highlights the most clinically relevant data and key studies in the adjuvant and metastatic breast cancer settings.
 
|
|
Colorectal Cancer Expert Recap
Alan P. Venook, MD, explores the most compelling data in colorectal cancer presented at the 2009 Clinical Oncology meeting.
|
|
Hematologic Malignancies
Edward A. Stadtmauer, MD, reviews the most important studies presented at the 2009 Clinical Oncology meeting in the settings of multiple myeloma, lymphomas, and leukemias.
|
|
Lung Cancer Expert Recap
David R. Gandara, MD, discusses significant clinical trial results and optimal treatment regimens for treating patients with lung cancer.
|
Expert Highlights
 |
Kathy D. Miller, MD, reviews breast cancer highlights, including the use of PARP inhibitors and HER2-targeted therapies; prognostic assays for selecting patients for chemotherapy; and treatment options for triple-negative breast cancer patients. (5 minutes)
|
 |
Download Audio |
 |
Richard M. Goldberg, MD, discusses recent data from the QUASAR validation study of prognostic biomarkers of recurrence in stage II disease, results from the NSABP C-08 study of mFOLFOX with or without bevacizumab in stage II/III colon cancer, findings from the ACCENT group’s meta-analyses of studies evaluating fluoropyrimidines with or without oxaliplatin or irinotecan in the adjuvant setting, and outcomes from ACCORD 12/0405 PRODIGE 2 and (STAR)-01. (10 minutes)
|
|
Download Audio |
 |
Edward A. Stadtmauer, MD, reviews key studies and new developments in multiple myeloma, non-Hodgkin’s lymphomas, and chronic lymphocytic leukemia. (9 minutes)
|
|
Download Audio |
 |
J. Tate Thigpen, MD, discusses important findings in ovarian cancer, including findings from the CALYPSO trial, outcomes of a study evaluating delayed or early treatment of patients with rising CA-125, and findings from a phase III trial of gemcitabine plus cisplatin and radiation in cervical cancer patients. (7 minutes)
|
|
Download Audio |
 |
Corey J. Langer, MD, FACP, discusses updates in non-small-cell lung cancer including findings from the phase III BR10 study in the adjuvant setting, new data from the phase II CALBG 30407 trial in locally advanced disease, and results from the phase III IPASS trial in patients with advanced disease. (6 minutes)
|
|
Download Audio |
Disclosures – Audio Expert Highlights
Kathy D. Miller, MD, has disclosed that she receives consulting fees from Genentech, fees for non-CME services from Genentech and Roche, and contracted research fees from Amgen, Genentech, GlaxoSmithKline, and Geron.
Richard M. Goldberg, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Genentech, Genomic Health, Myriad, Poniard, and sanofi-aventis.
Edward A. Stadtmauer, MD, has disclosed that he receives consulting fees and fees for non-CME services from Celgene and Millennium.
J. Tate Thigpen, MD, has no significant finiancial relationships to disclose.
Corey J. Langer, MD, FACP, has disclosed that he has served on the speakers bureaus for Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Ortho Biotech, OSI, and sanofi-aventis; has served as scientific advisor to Abbott, Abraxis, Amgen, AstraZeneca, Bayer-Onyx, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, ImClone, Intrabiotics, Pfizer, Pharmacyclics, sanofi-aventis, and Savient; and has received grant/research support from Active Biotech, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Cell Therapeutics, Eli Lilly and Company, Genentech, ImClone, Medimmune, Ortho Biotech, OSI, Pfizer, sanofi-aventis, Schering-Plough Research Institute, and Vertex.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
Recurrence Score Defined Prospectively Using Gene Expression Assay Predicts Recurrence Risk in Stage II Colon Cancer
The study is the first to illustrate that a gene expression assay can be used to independently predict colon cancer recurrence risk, according to investigators.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|